Jump to content

Poniard Gets European Orphan Status for SCLC Drug


Recommended Posts

Wed Oct 17, 2007 11:15am EDT

Oct 17 (Reuters) - Poniard Pharmaceuticals Inc (PARD.O: Quote, Profile, Research) said the European Commission granted its drug, picoplatin, orphan drug status for the treatment of small cell lung cancer.

This designation is given to drugs which may be used for conditions that affect no more than five in 10,000 persons in the European Union, the biopharmaceutical company said in a statement.

Poniard said Wednesday's status for the drug, which already has orphan drug status in the United States for the same condition, is based on the recommendation from a committee of the health regulator European Medicines Agency (EMEA). (Reporting by Varsha Tickoo in Bangalore)

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.